Table 3 High-intensity interval training rheumatoid arthritis cohort #2: skeletal muscle canonical pathways associated with improvements in disease activity

Proline biosynthesis II

3.84

4/5

OAT,PYCR1,PYCR2,PYCR3

Glycine cleavage complex

3.38

4/6

AMT,GCSH,GLDC,TBXT

Purine biosynthesis II

3.14

5/11

ADSS1,IMPDH1,PAICS

ADSS2,IMPDH2

Proline biosynthesis I

2.8

3/4

PYCR1,PYCR2,PYCR3

nNOS signaling in skeletal muscle cells

2.63

9/40

CACNA1A,CACNA1C,CACNA1I,CACNA2D4, CACNB4,CACNG8,CHRNA1,RYR1

CACNB1

Sertoli cell-sertoli cell junction signaling

2.36

24/181

CLDN14,CLDN18,CLDN19,ITGA3,MAP2K3,MYO7A,PRKAG2,PRKG2,SYMPK,TJAP1,TUBB8

ACTC1,LK,MAP3K6,MAPK9,MRAS,NECTIN1, RASD1,RRAS,SORBS1,SPTBN1,TUBA1A,TUBB2A, TUBB2B

L-DOPA degradation

2.25

2/2

COMT,LRTOMT

VDR/RXR activation

1.94

12/77

HOXA10,HSD17B2,IGFBP3,IGFBP5,KLK6,NCOR2, RXRB,SEMA3B,SULT2A1,WT1

CASR,TRPV6

Ethanol degradation II

1.88

6/27

ADH1C,AKR1A1,ALDH3A1,ALDH9A1

ACSS2,ALDH7A1

Estrogen receptor signaling

1.84

35/319

AGT,ATP5F1A,ATP5PB,BCL2,CACNA1A,CACNA1C,CTBP1,EGFR,ESR1,GNAO1,HIF1A,MED10,MED14, MED16,MED4, MED6, NCOR2,PLCB1,PRKAG2, TFAM,TYK2,VEGFC

CTBP2,EGF,FOXO6,MMP19,MMP20,MMP21,MRAS,MYL1,MYL6,PLCB2, POLR2B,RASD1,RRAS

HIF1α signaling

1.84

24/200

APEX1,ARAF,BMP6,CAMK1D,HIF1A,HSPA4, HSPA6,LDHB,MAP2K3,MKNK2,MMP19,MMP20, SLC2A14,SLC2A3,VEGFC

CCNG2,EGF,MDM2,MMP21,MRAS,PPP3R1,RAN,

RASD1,RRAS

Methylglyoxal degradation III

1.77

4/14

AKR1A1,DHRS11

AKR1C1/AKR1C2,AKR1C3

Estrogen-dependent breast cancer signaling

1.72

11/73

DHRS11,EGFR,ESR1,HSD17B11,HSD17B12, HSD17B2

AKR1C4,MRAS,RASD1,RRAS,TERT

Vitamin-C transport

1.6

5/23

NXN,SLC2A3,TXNRD3

AKR1C4,LRRC8A

2-KG dehydrogenase complex

1.52

2/4

DLST

OGDH

Branched-chain α-keto acid dehydrogenase complex^*#

1.52

2/4

BCKDHB,DBT

Neuroprotective role of THOP1 in Alzheimer’s disease

1.49

14/109

AGT,APP,GNRH2,GZMA,KLK12,KLK6,PRKAG2, PRSS3,SERPINA3

FAP,HLA-B,PRSS23,ST14,YWHAE

Glycogen degradation II

1.36

3/11

AGL,PGM5

TYMP